Search for a command to run...
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d3686095e174">Precision medicine, leveraging genomic and multi-omics data to tailor treatments, promises a new era of personalised healthcare. However, while healthcare could be precise, to achieve truly personalised care, other factors beyond omics must be considered. We are still fragmenting the person into their clinical building blocks. Traditional informed consent models are being challenged by their ethical and legal foundations, which are proving inadequate for this rapidly evolving field. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3686095e176">As part of the REPO4EU project, we aim to develop a large language model (LLM) capable of generating clinical trial information sheets and consent templates. We first established a systematic selection methodology to ensure the model is trained on a representative and relevant dataset. To select the proper trials for our LLM REPO4EU consent template, we initially developed a preliminary classification schema of trials in CTIS. During this phase, we incidentally discovered no uniformity in Europe regarding informed consent practices. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3686095e178">This finding prompted the establishment of clinical trial country cards to analyse the different approaches to informed consent within EU member states. These country cards will serve as a strategy to explain good and bad ethical practices in developing informed consent for precision medicine clinical trials. This communication will explore the core challenges in obtaining valid consent and propose a framework for a more ethical and practical approach, building on the insights gained from our analysis of European practices.